- Animal research (PDF 0.2 MB)
- Clinical study transparency (PDF 0.2 MB)
- Medicines for Patients with Rare Diseases (PDF 0.2 MB)
- Post-trial Access (PDF 0.1 MB)
- Novartis Position on Access to Unauthorized Novartis Products through Managed Access Programs (MAPs) (PDF 0.2 MB)
- Responsible Clinical Trials (PDF 0.1 MB)
- Novartis Commitment to Diversity in Clinical Trials (PDF 0.2 MB)
- Novartis Position on Investigator Initiated Trials (IITs) and Investigator Initiated Research (IIRs) (PDF 0.2 MB)
- Position on Scientific Publications (PDF 0.2 MB)